In the CONVINCE trial, colchicine reduced CRP levels in patients with non-cardioembolic stroke or transient ischaemic attack (TIA), but the primary composite outcome (recurrent ischaemic stroke, MI, cardiac arrest, or hospitalization) was not significantly reduced, partly due to premature trial termination related to funding constraints during the COVID-19 pandemic.113 Similarly, the CHANCE-3 trial, enrolling patients with minor-to-moderate ischaemic stroke or TIA and elevated high-sensitivity CRP, found no significant reduction in event recurrence at 90 days with colchicine treatment.114. This evidence concerns the gene CRP and cardiac arrest.